Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a potentially curative therapy for patients suffering from hematological malignancies via the donor immune system driven graft-versus-leukemia effect. However, the therapy is mainly limited by severe acute and chronic graft-versus-host...
Enregistré dans:
Auteurs principaux: | Lukas M. Braun, Robert Zeiser |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Frontiers Media S.A.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/8e05d6cf6e4145bcafbadad76c11be1c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
par: Joanne E. Davis, et autres
Publié: (2021) -
Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors
par: Daniele Cattaneo, et autres
Publié: (2021) -
The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review
par: Kamil D. Kaplanov
Publié: (2021) -
Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia
par: Leigh Naylor-Adamson, et autres
Publié: (2021) -
ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia
par: Tatiana E. Bialik, et autres
Publié: (2021)